AN2 Therapeutics Q3 net loss $16.7M; epetraborole Phase 3 enrollment underway

AN2 Therapeutics, Inc.

2023-Q3 EPS reported -$2.22

Net loss $16.7M for Q3 2023, up from $11.3M in Q3 2022; R&D and G&A expenses increased.
Cash and investments $150.2M at Sept 30; $70M raised in August stock offering; cash runway through summer 2025.
Phase 3 part of pivotal epetraborole trial in refractory MAC lung disease initiated; Phase 2 top-line data expected summer 2024.
Received Bill & Melinda Gates Foundation grant for TB/malaria; exclusive license for Chagas disease candidate AN2-502998.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AN2 Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $16.7 million.

Period: third quarter ended September 30, 2023
Net income: Net loss was $16.7 million
Result: reported results

Exact text from the filing

On November 9, 2023, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.